preview

18f Fludeoxyglucose Lab Report

Decent Essays

18F-fludeoxyglucose Chemical Structure: - Formulation: - 18F-FDG is synthesized by electrophilic fluorination with 18F2. Carrier free dissolved 18F-fluoride (18F-) ions in water is produced by proton bombardment of 18O-enriched water which causes a (n-p) reaction in 18O. 18F- is then separated from the aqueous solvent by trapping it on an ion-exchange column. It is then eluted with an acetonitrile solution of 2,2,2-cryptand and potassium carbonate and evaporated to give [(crypt-222) K]+ 18F-. In the above reaction, intermediate (2) produced is treated with mannose triflate (1) which gives fluorinated deoxyglucose (3) by SN2 reaction by displacing the triflate group by fluoride anion. Finally, 18F-FDG (4) is produced by base hydrolysis …show more content…

11C-choline is distributed mainly to the pancreas, kidneys, liver, spleen and colon. The relatively low urinary excretion of radioactivity shows that renal distribution is maximum in the organ itself, rather than via formation of urine. After intravenous administration, 11C-choline undergoes metabolism. 11C-betaine is the major metabolite in blood detected after metabolism. The study in patients with prostate cancer or brain disorders showed that the fractional activities of 11C-choline and 11C-betaine in human arterial plasma reached plateau within 25 minutes. 11C-betaine represented 82% ± 9% of the total 11C detected at that time. A small amount of unmetabolized 11C-choline was also detected within the blood at the final sampling time at around 40 minutes. Urinary excretion of 11C-choline was < 2% of the injected radioactivity at 1.5 hours after injection of the drug. The rate of 11C-choline excretion in urine was 0.014 mL/min. Choline is a natural compound with no known toxic effects at levels present in the11C-Choline injection. Long term studies have not been performed to evaluate the carcinogenic potential of …show more content…

Vial A consists of 0.9 mg of bicisate dihydrochloride, 0.36 mg of disodium EDTA dihydrate acting as a transchelating agent, 24 mg of mannitol acting as a bulking agent for lyophilization process, 12-72 µg of SnCl2.2H2O and a reducing agent. Vial B consists of a buffer solution of 4.1 mg of Na2HPO4.7H2O, 0.46 mg of NaH2PO4.H2O and 1 ml of sterile water for injection. They are stored at 15-25 ºC and vial A must be protected from light.) and sodium (99mTc) pertechnetate

Get Access